http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of PlenityTM in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults
-
New Plenity™ Pivotal Safety and Efficacy Data to be Presented at ObesityWeek 2019
-
PureTech Announces Board Change
-
PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
-
PureTech Announces Issuance of U.S. Patent Covering Compositions of Matter for Immuno-Oncology Program Targeting Galectin-9
-
PureTech Establishes New Corporate Headquarters in Boston’s Seaport District to Support Expansion and Acceleration of Internal R&D Pipeline
-
PureTech Health to Present at Jefferies 2019 Healthcare Conference
-
Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massac
-
PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week
-
Gelesis Awarded $10.6 (€9.4) Million Grant to Support Commercial Manufacturing of PLENITY™
-
PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform
-
Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management
-
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Prevents Harmful Effects of a High-Fat Diet
-
PureTech Health Announces Presentation of Internal Immuno-Oncology Programs at American Association for Cancer Research (AACR) Annual Meeting
-
Gelesis Presents Expanded Data Showing Impact of Gelesis100 Hydrogel on Patients with Prediabetes, Untreated Diabetes, and Elevated Insulin Resistance
-
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Restores Gut Barrier Function
-
Gelesis Announces Three Presentations at Annual Endocrine Society Meeting
-
PureTech Health to Present at Two Upcoming Investor Conferences
-
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
-
Pivotal Weight Loss Data for Gelesis100 Published in Obesity, Including Predictors of Response
-
PureTech Health to Present at Jefferies 2018 London Healthcare Conference
-
Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018
-
PureTech Health Collaborator Publishes in Nature Neuroscience Highlighting Key Role of Brain Lymphatics in Neuroinflammatory Conditions Like Multiple Sclerosis
-
PureTech Health Collaborator Publishes in Journal Nature Regarding New Insights into Key Role of Brain Lymphatics in Alzheimer’s and Other Neurodegenerative Diseases
-
PureTech Health Announces Collaboration with Roche to Advance Technology for Oral Administration of Antisense Oligonucleotides
-
Harry Leider, Former Chief Medical Officer of Walgreens, Joins Gelesis as Chief Medical Officer, and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, Joins the Gelesis Board of Dire
-
PureTech Health to Present at Jefferies 2018 Global Healthcare Conference
-
PureTech Health Appoints Joep Muijrers as Chief Financial Officer
-
Gelesis Raises $30 Million to Prepare for Potential Launch of Lead Product
-
Camtek Ltd. (Nasdaq: CAMT) to Ring The Nasdaq Stock Market Closing Bell
-
PureTech Health to Present at Piper Jaffray 2017 Healthcare Conference
-
PureTech Health to Present at Jefferies 2017 Healthcare Conference in London
-
Vedanta Biosciences Awarded Up To $5.4 Million from CARB-X to Accelerate Development of VE303, a Novel Human Microbiome-Derived Treatment for Serious Bacterial Infection
-
Gelesis100 Achieves Significant Weight Loss with Excellent Safety Profile in Pivotal Study
-
PureTech Health Notes U.S. Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Speech
-
PureTech Health Exclusively Licenses Novel Milk-Derived Exosome Technology for Oral Administration of Biologics, Nucleic Acids, and Complex Small Molecules
-
PureTech Health Exclusively Licenses Glyph Technology from Monash University to Harness Lymphatic Biology
-
PureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Alivio Inflammation-Targeting Technology
-
PureTech Health to Present at Jefferies 2017 Global Healthcare Conference
-
Sync Project Announces New Investors and Accelerates Development of Personalized Music Health Platform
-
PureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections
-
PureTech Health Announces Licensing Agreement between Commense and the University of British Columbia for Microbiome-Derived Therapy
-
resTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer
-
PureTech Health Advances New Program Targeting Immunosuppressive Gamma Delta T Cells and Related Mechanisms
-
Akili Announces Results from Pilot Study Showing Treatment with Project EVO™ Improves Cognitive Control in Children with Sensory Processing Dysfunction and Attentional Deficits
-
PureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 Programs
-
PureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy
-
PureTech Health to Present at the Cowen and Company 37th Annual Health Care Conference
-
PureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer
-
PureTech Health to Present at the Leerink Partners 6th Annual Global Healthcare Conference

